(E)-8-BENZYLIDENE DERIVATIVES OF 2-METHYL-5-(3-HYDROXYPHENYL)MORPHANS - HIGHLY SELECTIVE LIGANDS FOR THE SIGMA(2) RECEPTOR SUBTYPE

被引:18
作者
BERTHA, CM
VILNER, BJ
MATTSON, MV
BOWEN, WD
BECKETTS, K
XU, H
ROTHMAN, RB
FLIPPENANDERSON, JL
RICE, KC
机构
[1] NIDDKD,MED CHEM LAB,BETHESDA,MD 20892
[2] NIDA,ADDICT RES CTR,CLIN PSYCHOPHARMACOL SECT,BALTIMORE,MD 21224
[3] USN,RES LAB,STRUCT MATTER LAB,WASHINGTON,DC 20375
关键词
D O I
10.1021/jm00024a005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The determination of the structure and function of the sigma receptor subtypes and their physiological role(s) has been impeded by the unavailability of selective ligands. We have developed a new class of sigma subtype selective receptor ligands that are (E)-8-benzylidene derivatives of the synthetic opioid (+/-)-, (+)-, and (-)-2-methyl-5-(3-hydroxyphenyl)morphan-7-one (1). The derivatives can be prepared by reaction of 1, (+)-1, and (-)-1 with the appropriate benzaldehyde under Claisen-Schmidt conditions. Incorporation of substituted (E)-8-benzylidene moieties onto the 7-keto precursor of (+)-2-methyl-5-(3-hydroxyphenyl)morphan, (+)-1, produces compounds (-)-2 through (-)-7 (5.8-32.0 nM, sigma(1)), which have between a 25- and 131-fold increase in affinity for the sigma(1) receptor subtype relative to the keto precursor (+)-1 (K-i 762 nM, sigma(1)). Compound (-)-2 is the most selective of this group (16-fold) for the sigma(1) subtype versus sigma(2). Substitution of an (E)-8-benzylidene moiety onto the 7-keto precursor of(-)-2-methyl-5-(3-hydroxyphenyl)morphan, (-)-1, produces compounds (+)-2-(+)-9 (6.4-52.6 nM, sigma(2)), which have at least a 475-3906-fold increase in affinity for the sigma(2) receptor subtype relative to the keto precursor (-)-1 (K-i = 25 x 10(3) nM). This enhancement of sigma(2) receptor affinity is accompanied by substantial selectivity of all of these dextrorotatory products for the sigma(2) relative to the sigma(1) subtype (32-238-fold), and thus, they are among the most sigma(2) subtype selective compounds currently known. Furthermore, the sigma(1) subtype is highly enantioselective for the levorotatory isomers, (-)-2-(-)-7 (41-1034-fold), whereas the sigma(2) subtype is only somewhat enantioselective for the dextrorotatory isomers, (+)-2-(+)-7 (2.6-9.3-fold). All of these derivatives retain substantial affinity for the mu opioid receptor. Despite the high affinity of the dextrorotatory derivatives for the mu opioid receptor, the high affinity and selectivity for sigma(2) over sigma(1) sites will surely prove beneficial as tools for the delineation of the function and physiological role of sigma(2) receptors.
引用
收藏
页码:4776 / 4785
页数:10
相关论文
共 104 条
[1]   PHENCYCLIDINE AND SIGMA-RECEPTORS IN RAT SPINAL-CORD - BINDING CHARACTERIZATION AND QUANTITATIVE AUTORADIOGRAPHY [J].
AANONSEN, LM ;
SEYBOLD, VS .
SYNAPSE, 1989, 4 (01) :1-10
[2]   CHARACTERIZATION OF BINDING-SITES FOR [H-3] DTG, A SELECTIVE SIGMA-RECEPTOR LIGAND, IN THE SHEEP PINEAL-GLAND [J].
ABREU, P ;
SUGDEN, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 171 (02) :875-881
[3]   PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF SIGMA-SITES IN DTG-INDUCED CONTRALATERAL CIRCLING IN RATS [J].
BASTIANETTO, S ;
PERRAULT, G ;
SANGER, DJ .
NEUROPHARMACOLOGY, 1995, 34 (01) :107-114
[4]  
BEM WT, 1991, CANCER RES, V51, P6558
[5]   A MARKED CHANGE OF RECEPTOR AFFINITY OF THE 2-METHYL-5-(3-HYDROXYPHENYL)MORPHANS UPON ATTACHMENT OF AN (E)-8-BENZYLIDENE MOIETY - SYNTHESIS AND EVALUATION OF A NEW CLASS OF SIGMA-RECEPTOR LIGANDS [J].
BERTHA, CM ;
MATTSON, MV ;
FLIPPENANDERSON, JL ;
ROTHMAN, RB ;
XU, H ;
CHA, XY ;
BECKETTS, K ;
RICE, KC .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (19) :3163-3170
[6]   PROBES FOR NARCOTIC RECEPTOR-MEDIATED PHENOMENA .20. ALTERATION OF OPIOID RECEPTOR SUBTYPE SELECTIVITY OF THE 5-(3-HYDROXYPHENYL)MORPHANS BY APPLICATION OF THE MESSAGE-ADDRESS CONCEPT - PREPARATION OF DELTA-OPIOID RECEPTOR LIGANDS [J].
BERTHA, CM ;
FLIPPENANDERSON, JL ;
ROTHMAN, RB ;
PORRECA, F ;
DAVIS, P ;
XU, H ;
BECKETTS, K ;
CHA, XY ;
RICE, KC .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) :1523-1537
[7]  
BERTHA CM, 1994, 208TH NAT M AM CHEM, P189
[8]  
BONHAUS DW, 1993, J PHARMACOL EXP THER, V267, P961
[9]  
BOOTH RG, 1993, J PHARMACOL EXP THER, V44, P1232
[10]  
BOOTH RG, 1994, MED CHEM RES, V4, P225